WARPTECHNEWS · LAB

Home AI Business Tech Archive

FDA accepts new drug application for ralinepag in PAH — Warptech Lab News

WARPTECH LAB NEWS

Warptech Lab News aggrega le notizie più rilevanti da oltre 700 fonti internazionali, con classificazione AI, TL;DR sintetici e timeline cluster su singole storie.

Navigazione

Home
Archivio
Editor's Brief
Cerca
Il tuo account
Newsletter tech/AI

Informazioni legali

Privacy Policy
Termini di servizio
Cookie Policy

© 2026 Sparktech S.R.L. — Tutti i diritti riservati. Sito gestito e manutenuto da Sparktech S.R.L.

Sede legale: Corso Libertà 55, 13100 Vercelli (VC), Italia · P.IVA / C.F. 02835910023 · Contatti: admin@warptechlab.com

FDA accepts new drug application for ralinepag in PAH

The FDA accepted United Therapeutics’ new drug application for ralinepag, a once-daily oral prostacyclin, for the treatment of pulmonary arterial hypertension, according to a press release.The new drug application (NDA) included data from the multicenter, global, randomized, double-blind, placebo-controlled, event-driven phase 3 ADVANCE OUTCOMES trial, which were presented at the American

mercoledì 26 agosto 2026 New tab

920 words~4 min read

August 26, 2026

2 min read

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Other newsrooms on this story

· 4 sources

Full timeline →

morningstar.com·Aug 24, 2026 · 5 g fa
United Therapeutics Corporation Announces FDA Filing Acceptance of New Drug Application for Ralinepag to Treat Pulmonary Arterial Hypertension
morningstar.com·Aug 28, 2026 · 1 g fa
United Therapeutics Presents Data at The European Society of Cardiology Congress 2026 and The European Respiratory Society International Congress 2026
morningstar.com·Aug 24, 2026 · 5 g fa
Pulnovo Medical Announces First Two U.S. Patients Enrolled in PULSE-LHD IDE Clinical Trial of Pulmonary Artery Denervation in Treating Pulmonary Hypertension Associated with Left Heart Disease
fiercepharma.com·Aug 28, 2026 · 1 g fa
Priovant pushes ex-Pfizer asset across FDA finish line in rare skin and muscle disease

Related reading

morningstar.com

United Therapeutics Corporation Announces FDA Filing Acceptance of New Drug…

United Therapeutics Corporation Announces FDA Filing Acceptance of New Drug Application for Ralinepag to Treat Pulmonary Arterial…

morningstar.com·5 g fa

Add-on ralinepag delays first clinical worsening event in PAH

ORLANDO — Ralinepag, a prostacyclin receptor agonist, added to background therapy decreased the risk for a clinical worsening…

healio.com·3 mesi fa

medpagetoday.com

New Drug Prevents Worsening Pulmonary Arterial Hypertension in Major Trial Win

Phase III data favorable for oral ralinepag, a once-daily selective prostacyclin receptor agonist

medpagetoday.com·29 g fa

morningstar.com

United Therapeutics Corporation Announces ADVANCE OUTCOMES Study of Ralinepag…

United Therapeutics Corporation Announces ADVANCE OUTCOMES Study of Ralinepag Presented at ATS 2026

morningstar.com·3 mesi fa

Treprostinil palmitil inhalation powder has favorable safety, efficacy in PAH…

Among patients with pulmonary arterial hypertension, once-daily treprostinil palmitil inhalation powder for 12 months was well…

healio.com·1 mese fa

morningstar.com

United Therapeutics Presents Data at The European Society of Cardiology…

United Therapeutics Presents Data at The European Society of Cardiology Congress 2026 and The European Respiratory Society…

morningstar.com·1 g fa